uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions.

Bone Res · 2020 · PMC7165173 · PMID 32337090

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

This in-depth analysis is highly significant in developing a therapeutic approach for patients with breast cancer and may be of particular utility for clinical development in patients with TNBC, where the first targeted therapy (Atezolizumab) was only recently approved.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.